Randomized, Open-Label, Safety Pilot Study of Multiple Subcutaneous and Intramuscular Injections of Niagen® Plus
Latest Information Update: 03 Dec 2025
At a glance
- Drugs Nicotinamide riboside (Primary) ; Nicotinamide riboside (Primary)
- Indications Fatigue
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Niagen Bioscience
Most Recent Events
- 03 Dec 2025 New trial record